Incidence, Microbiological Studies, and Factors Associated With Prosthetic Joint Infection After Total Knee Arthroplasty.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
02 10 2023
Historique:
medline: 1 11 2023
pubmed: 31 10 2023
entrez: 31 10 2023
Statut: epublish

Résumé

Despite the frequency of total knee arthroplasty (TKA) and clinical implications of prosthetic joint infections (PJIs), knowledge gaps remain concerning the incidence, microbiological study results, and factors associated with these infections. To identify the incidence rates, organisms isolated from microbiological studies, and patient and surgical factors of PJI occurring early, delayed, and late after primary TKA. This cohort study obtained data from the US Department of Veterans Affairs (VA) Corporate Data Warehouse on patients who underwent elective primary TKA in the VA system between October 1, 1999, and September 30, 2019, and had at least 1 year of care in the VA prior to TKA. Patients who met these criteria were included in the overall cohort, and patients with linked Veterans Affairs Surgical Quality Improvement Program (VASQIP) data composed the VASQIP cohort. Data were analyzed between December 9, 2021, and September 18, 2023. Primary TKA as well as demographic, clinical, and perioperative factors. Incident hospitalization with early, delayed, or late PJI. Incidence rate (events per 10 000 person-months) was measured in 3 postoperative periods: early (≤3 months), delayed (between >3 and ≤12 months), and late (>12 months). Unadjusted Poisson regression was used to estimate incidence rate ratios (IRRs) with 95% CIs of early and delayed PJI compared with late PJI. The frequency of organisms isolated from synovial or operative tissue culture results of PJIs during each postoperative period was identified. A piecewise exponential parametric survival model was used to estimate IRRs with 95% CIs associated with demographic and clinical factors in each postoperative period. The 79 367 patients (median (IQR) age of 65 (60-71) years) in the overall cohort who underwent primary TKA included 75 274 males (94.8%). A total of 1599 PJIs (2.0%) were identified. The incidence rate of PJI was higher in the early (26.8 [95% CI, 24.8-29.0] events per 10 000 person-months; IRR, 20.7 [95% CI, 18.5-23.1]) and delayed periods (5.4 [95% CI, 4.9-6.0] events per 10 000 person-months; IRR, 4.2 [95% CI, 3.7-4.8]) vs the late postoperative period (1.3 events per 10 000 person-months). Staphylococcus aureus was the most common organism isolated overall (489 [33.2%]); however, gram-negative infections were isolated in 15.4% (86) of early PJIs. In multivariable analyses, hepatitis C virus infection, peripheral artery disease, and autoimmune inflammatory arthritis were associated with PJI across all postoperative periods. Diabetes, chronic kidney disease, and obesity (body mass index of ≥30) were not associated factors. Other period-specific factors were identified. This cohort study found that incidence rates of PJIs were higher in the early and delayed vs late post-TKA period; there were differences in microbiological cultures and factors associated with each postoperative period. These findings have implications for postoperative antibiotic use, stratification of PJI risk according to postoperative time, and PJI risk factor modification.

Identifiants

pubmed: 37906194
pii: 2811143
doi: 10.1001/jamanetworkopen.2023.40457
pmc: PMC10618849
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2340457

Subventions

Organisme : NIAAA NIH HHS
ID : P01 AA029545
Pays : United States
Organisme : NIAAA NIH HHS
ID : U10 AA013566
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA020790
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA020794
Pays : United States
Organisme : NIAID NIH HHS
ID : F32 AI164809
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI055435
Pays : United States

Références

JAMA Surg. 2018 Aug 1;153(8):768-769
pubmed: 29617543
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
J Int Med Res. 2021 Mar;49(3):3000605211002784
pubmed: 33787371
Clin Orthop Relat Res. 2010 Jan;468(1):52-6
pubmed: 19669386
J Bone Joint Surg Am. 2013 May 1;95(9):775-82
pubmed: 23636183
PLoS One. 2011;6(8):e23224
pubmed: 21853091
AIDS. 2009 Jun 19;23(10):1227-34
pubmed: 19444074
Lancet Infect Dis. 2019 Jun;19(6):589-600
pubmed: 31005559
Infect Dis Clin North Am. 2018 Dec;32(4):843-859
pubmed: 30241717
Clin Infect Dis. 1998 Nov;27(5):1247-54
pubmed: 9827278
Ann Surg. 1998 Oct;228(4):491-507
pubmed: 9790339
J Bone Joint Surg Am. 2014 Sep 17;96(18):e158
pubmed: 25232088
BMC Infect Dis. 2017 Aug 25;17(1):592
pubmed: 28841913
Clin Orthop Relat Res. 2012 Oct;470(10):2695-701
pubmed: 22773393
J Arthroplasty. 2015 Jul;30(7):1197-202
pubmed: 25697889
J Orthop. 2021 Feb 20;24:111-120
pubmed: 33679036
Clin Infect Dis. 1997 Dec;25(6):1310-7
pubmed: 9431369
J Arthroplasty. 2018 Jan;33(1):36-40
pubmed: 28844769
J Am Acad Orthop Surg. 2001 Jan-Feb;9(1):9-17
pubmed: 11174159
Infect Control Hosp Epidemiol. 2015 Oct;36(10):1198-207
pubmed: 26154882
Circulation. 2019 Aug 6;140(6):449-458
pubmed: 31280589
Am J Manag Care. 2015 Feb 01;21(2):e114-8
pubmed: 25880486
Orthop Clin North Am. 2023 Jul;54(3):259-267
pubmed: 37271554
J Arthroplasty. 2019 May;34(5):947-953
pubmed: 30765229
Circulation. 2018 Jul 17;138(3):255-265
pubmed: 29535090
Nicotine Tob Res. 2011 Dec;13(12):1233-9
pubmed: 21911825
J Arthroplasty. 2022 Feb;37(2):367-372.e1
pubmed: 34678445
J Rheumatol. 2019 Sep;46(9):1134-1140
pubmed: 30988126
BMC Musculoskelet Disord. 2017 Dec 21;18(1):544
pubmed: 29268748
Osteoarthritis Cartilage. 2010 Dec;18(12):1639-42
pubmed: 20950694
J Arthroplasty. 2008 Oct;23(7):984-91
pubmed: 18534466
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
Anaesthesia. 2019 Mar;74(3):373-379
pubmed: 30648259
J Arthroplasty. 2018 Jul;33(7):2218-2224
pubmed: 29573917
J Arthroplasty. 2015 Sep;30(9):1492-7
pubmed: 25865815
Am J Infect Control. 1997 Oct;25(5):381-6
pubmed: 9343620
J Arthroplasty. 2022 Apr;37(4):683-687.e1
pubmed: 34954020
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1490-6
pubmed: 22623324
J Arthroplasty. 2021 Mar;36(3):1023-1028
pubmed: 33067093
J Knee Surg. 2021 Aug;34(10):1110-1119
pubmed: 32131096
Surg Infect (Larchmt). 2013 Feb;14(1):73-156
pubmed: 23461695
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Knee Surg Relat Res. 2020 Feb 12;32(1):12
pubmed: 32660587
Clin Microbiol Infect. 2019 Mar;25(3):353-358
pubmed: 29803842
J Arthroplasty. 2018 Apr;33(4):1258-1264
pubmed: 29325724
AIDS. 2004 Jan 1;18 Suppl 1:S49-59
pubmed: 15075498
Clin Microbiol Infect. 2022 Feb;28(2):255-259
pubmed: 34129907
Med Care. 2006 Aug;44(8 Suppl 2):S25-30
pubmed: 16849965
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:129-40
pubmed: 22262599
Infect Dis Clin North Am. 2005 Dec;19(4):931-46
pubmed: 16297740
Surg Infect (Larchmt). 2015 Dec;16(6):657-68
pubmed: 26244748
Aliment Pharmacol Ther. 2008 Feb 1;27(3):274-82
pubmed: 17996017
Anesth Analg. 2003 Jun;96(6):1553-1557
pubmed: 12760974
Clin Microbiol Rev. 2014 Apr;27(2):302-45
pubmed: 24696437
PLoS One. 2016 Mar 03;11(3):e0150866
pubmed: 26938768
Clin Orthop Relat Res. 2015 Oct;473(10):3163-72
pubmed: 25995174
Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1184-1191
pubmed: 34170057
Arch Orthop Trauma Surg. 2020 Feb;140(2):239-245
pubmed: 31707484
ANZ J Surg. 2021 Nov;91(11):2308-2321
pubmed: 34405518
J Arthroplasty. 2019 Jan;34(1):116-122
pubmed: 30337254
Am J Infect Control. 2019 Oct;47(10):1270-1272
pubmed: 31153712
JAMA. 2012 Sep 26;308(12):1227-36
pubmed: 23011713
Ann Transl Med. 2015 Sep;3(16):233
pubmed: 26539450
JAMA Cardiol. 2017 May 1;2(5):536-546
pubmed: 28384660
Bone Joint J. 2019 Jun;101-B(6):667-674
pubmed: 31154838
J Arthroplasty. 2018 Oct;33(10):3238-3245
pubmed: 29914821

Auteurs

Erica J Weinstein (EJ)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Center for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Alisa J Stephens-Shields (AJ)

Center for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Craig W Newcomb (CW)

Center for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Randi Silibovsky (R)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Charles L Nelson (CL)

Department of Orthopedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Judith A O'Donnell (JA)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Laurel J Glaser (LJ)

Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Evelyn Hsieh (E)

Veterans Affairs (VA) Connecticut Health System, West Haven.
Section of Rheumatology, Allergy and Immunology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.

Jennifer S Hanberg (JS)

Veterans Affairs (VA) Connecticut Health System, West Haven.
Department of Medicine, Massachusetts General Hospital, Boston.

Janet P Tate (JP)

Veterans Affairs (VA) Connecticut Health System, West Haven.
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.

Kathleen M Akgün (KM)

Section of Pulmonary, Critical Care, and Sleep Medicine, VA Connecticut Health System, West Haven.
Section of Pulmonary, Critical Care, and Sleep Medicine, Yale University School of Medicine, New Haven, Connecticut.

Joseph T King (JT)

Veterans Affairs (VA) Connecticut Health System, West Haven.
Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut.

Vincent Lo Re (V)

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Center for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH